These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35871235)

  • 21. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
    Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
    Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression.
    Boussouar A; Tortereau A; Manceau A; Paradisi A; Gadot N; Vial J; Neves D; Larue L; Battistella M; Leboeuf C; Lebbé C; Janin A; Mehlen P
    Cancer Res; 2020 Feb; 80(4):747-756. PubMed ID: 31806640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
    Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
    Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and Validation of
    Li Z; Wang X; Yang Y; Shi F; Zhang W; Wang Q; Wang S
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
    Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():721409. PubMed ID: 34795662
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma.
    Zhuo M; Gorgun FM; Tyler DS; Englander EW
    Pigment Cell Melanoma Res; 2021 May; 34(3):605-617. PubMed ID: 33124186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
    Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
    Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
    Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
    Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    Sarfaty M; Golkaram M; Funt SA; Al-Ahmadie H; Kaplan S; Song F; Regazzi A; Makarov V; Kuo F; Ostrovnaya I; Seshan V; Zhao C; Greenbaum B; Liu L; Rosenberg JE; Chan TA
    J Clin Oncol; 2023 Jun; 41(17):3225-3235. PubMed ID: 36927002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
    Jia Q; Wang J; He N; He J; Zhu B
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer.
    Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY
    Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
    Front Immunol; 2022; 13():955800. PubMed ID: 36405701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Association of
    Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
    Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.